Bristol Myers Squibb

Bristol Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol Myers Squibb

Simplify's Rating
Why Bristol Myers Squibb is rated
B
Rated B on Competitive Edge
Rated A on Growth Potential
Rated C on Differentiation

Industries

Biotechnology

Healthcare

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Overview

Company Historically Provides H1B Sponsorship

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet high safety and quality standards. Unlike many competitors, BMS emphasizes sustainability and corporate responsibility, focusing on Environmental, Social, and Governance (ESG) goals. Their goal is to improve patient outcomes by providing both innovative and affordable healthcare solutions.

Simplify Jobs

Simplify's Take

What believers are saying

  • Chris Shibutani's appointment may drive strategic growth and innovation at BMS.
  • Advancements in targeted protein degradation enhance therapeutic offerings in oncology.
  • Partnership with BioNTech could provide a competitive edge against Merck's Keytruda.

What critics are saying

  • Antitrust litigation over Pomalyst could impact BMS's market position in oncology.
  • Reliance on real-world data presents challenges in data quality and implementation.
  • High costs and technical challenges in space research could affect treatment feasibility.

What makes Bristol Myers Squibb unique

  • BMS collaborates with BioNTech for next-gen cancer immunotherapy, enhancing oncology portfolio.
  • Focus on real-world data strategies could lead to faster drug market entry.
  • Developing bone disease treatments in space positions BMS as a leader in innovative research.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$17914M

Above

Industry Average

Funded Over

2 Rounds

Post IPO Debt funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Debt Funding Comparison
Coming Soon

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Stock Price

Company News

ISS National Lab
Jul 7th, 2025
This is Not the Time to Cut Space-enabled Medical Research

Bristol-Myers Squibb is developing novel bone disease treatments in space, and the National Stem Cell Foundation is studying 3D brain organoids derived from patients with Parkinson's disease in microgravity to observe disease progression more rapidly with the aim of identifying potential biomarkers for early diagnosis and therapeutic targets.

The Pharma Letter
Jun 26th, 2025
Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst

Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst.

Unlearn
Jun 24th, 2025
The Best 15 Minutes You'll Spend on Clinical Trials Today

At the 2025 "Digital Breakthrough for Pharma" Summit hosted by Bristol Myers Squibb, Unlearn's co-founder and machine learning scientist, Aaron Smith, took the stage to explain exactly how that vision is now a reality.

ROI-NJ
Jun 13th, 2025
Bristol Myers Squibb Names Shibutani As Evp, Chief Strategy Officer

Bristol Myers Squibb (BMS) this week appointed Chris Shibutani as executive vice president, chief strategy officer, effective immediately. Shibutani’s role is a new position on the BMS leadership team. The announcement was made on a LinkedIn post.Shibutani will lead the development and advancement of the company’s long-term strategic plan, collaborating across the enterprise to drive innovation and growth. He brings more than 25 years of experience in the financial services industry covering global pharmaceutical, biotechnology and medical device industries.Prior to BMS, Shibutani served as managing director in the global investment research division at Goldman Sachs. Previous roles include senior analyst positions at Hambrecht & Quist, Cowen, UBS, and J.P. Morgan.Before his career in finance, Shibutani was a physician trained in anesthesiology and critical care medicine at Massachusetts General Hospital and practiced at Memorial Sloan Kettering Cancer Center

PharmaData
Jun 13th, 2025
Bristol Myers Squibb Highlights Targeted Protein Degradation Data, Including CELMoD Agents, at EHA 2025

Bristol Myers Squibb highlights targeted protein degradation advances, including CELMoD agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy.

Recently Posted Jobs

Sign up to get curated job recommendations

Bristol Myers Squibb is Hiring for 428 Jobs on Simplify!

Find jobs on Simplify and start your career today

đź’ˇ
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →